Top
Topic: SBRT and Immunotherapy for the Management of HCC: a recent Appraisal

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Dec 2019

Guest Editor(s)

  • Jia Fan, MD
    Department of Liver Surgery, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai 200032, P.R. China.
    Department of Molecular Cell Biology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China.

    E-mail

Special Issue Introduction

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, leading to more than 700 thousand deaths annually. In recent years, immunotherapy has emerged as a novel, effective systemic treatment for advanced HCC and potentially suppress tumor recurrence and metastasis. However, the objective response rate of simply immunologic agent treatment for HCC is still unsatisfactory. The combination of conventional treatments including stereotactic body radiation therapy (SBRT) with specific immunotherapeutic approaches may dramatically improve outcome of HCC patients. Moreover, the advancement of SBRT techniques has allowed for a safer administration of higher levels of dose to liver cancer while minimizing the potential liver toxicities. In this edition of Hepatoma Research, we will discuss new advances in SBRT, immunotherapy, and combined strategies for the treatment of patients with liver cancer.

Submission Deadline

30 Dec 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/hres/default.aspx
Submission Deadline: 30 Dec 2019
Contacts: Haidi Ding, Assistant Editor, editor001@hrjournal.net

Published Articles

This special issue is now open for submission.